Results 21 to 30 of about 248,501 (390)

The Role of Peroxisome Proliferator-Activated Receptors in Preeclampsia

Cells, 2023
Preeclampsia is a common pregnancy-related hypertensive disorder. Often presenting as preexisting or new-onset hypertension complicated by proteinuria and/or end-organ dysfunction, preeclampsia significantly correlates with maternal and perinatal ...
Iason Psilopatis, Kleio Vrettou, Florian Nima Fleckenstein, Stamatios Theocharis   +3 more
doaj   +1 more source

Peroxisome Proliferator-Activated Receptor alpha (PPAR alpha) down-regulation in cystic fibrosis lymphocytes [PDF]

, 2006
Background: PPARs exhibit anti-inflammatory capacities and are potential modulators of the inflammatory response. We hypothesized that their expression and/or function may be altered in cystic fibrosis (CF), a disorder characterized by an excessive host ...
A Augarten, A Linden, A Madej, A Trifilieff, AA Ionescu, AE Lovett-Racke, AP Sampson, B Staels, BM Forman, C Andersson, C Hubeau, C Hubeau, DC Jones, E Dagli, F Akbiyik, F McAllister, G Chinetti, H Pall, I Inoue, J Carlstedt-Duke, JD Dignam, JD Tugwood, JH Parmentier, JL Su, JM Shipley, JP Despres, JT Zakrzewski, K Balough, K Beier, KA Kreuzer, LS Nixon, M Ollero, M Roulet, MA Birrell, ME Poynter, N Marx, N Marx, P Delerive, P Greally, P Reineck, PM Farrell, PR Devchand, RB Moss, RB Moss, RB Moss, RU Sorensen, SD Freedman, SM Loitsch, SW Chung, TA Waldmann, TP Dean, TZ Khan, W Wahli, Z Israelian-Konaraki   +53 more
core   +4 more sources

The pathophysiological function of peroxisome proliferator-activated receptor-γ in lung-related diseases

Respiratory Research, 2005
Research into respiratory diseases has reached a critical stage and the introduction of novel therapies is essential in combating these debilitating conditions.
Lin Diana, Kota Bhavani, Razmovski-Naumovski Valentina, Huang Tom, Roufogalis Basil D   +4 more
doaj   +1 more source

PPAR gamma pro12Ala polymorphism and type 2 diabetes: a study in a spanish cohort [PDF]

, 2014
Type 2 diabetes (T2D) is a disease whose occurrence is increasing prevalent in westernized civilizations and is responsible for the proliferation in the morbidity and total mortality of patients with cardiovascular diseases, worldwide.
Cieza Borrella, C, Corral Gudino, L, González Sarmiento, R, Makena Hoghtower, C, Mayoral, R, Miramontes González, JP   +5 more
core   +1 more source

Resistin / Fizz3 Expression in Relation to Obesity and Peroxisome Proliferator–Activated Receptor-γ Action in Humans [PDF]

Diabetes, 2001
David B. Savage, Ciaran Sewter, Ellen S. Klenk, David G. Segal, Antonio Vidal‐Puig, Robert V. Considine, Stephen O’Rahilly   +6 more
openalex   +2 more sources

The case for intraocular delivery of PPAR agonists in the treatment of diabetic retinopathy

BMC Ophthalmology, 2012
Background Systemic therapeutics targeting the peroxisome proliferator-activated receptors have been found to be beneficial in the treatment of diabetic retinopathy.
Treacy Maxwell P, Hurst Tara P
doaj   +1 more source

Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.

Gastroenterology, 2016
BACKGROUND & AIMS Elafibranor is an agonist of the peroxisome proliferator-activated receptor-α and peroxisome proliferator-activated receptor-δ. Elafibranor improves insulin sensitivity, glucose homeostasis, and lipid metabolism and reduces inflammation.
V. Ratziu, S. Harrison, S. Francque, P. Bedossa, P. Lehert, L. Serfaty, M. Romero‐Gomez, J. Boursier, M. Abdelmalek, Steve Caldwell, J. Drenth, Q. Anstee, D. Hum, Rémy Hanf, A. Roudot, S. Megnien, B. Staels, A. Sanyal   +17 more
semanticscholar   +1 more source

Balaglitazone reverses P-glycoprotein-mediated multidrug resistance via upregulation of PTEN in a PPARγ-dependent manner in leukemia cells

Tumor Biology, 2017
Multidrug resistance in tumor cells is still a big challenge in cancer treatment. Therefore, identification ofsafe and effective multidrug resistance–reversing compounds with minimal side effects is an important approach in cancer treatment.
Bahman Yousefi, Ako Azimi, Maryam Majidinia, Vahid Shafiei-Irannejad, Reza Badalzadeh, Behzad Baradaran, Nosratollah Zarghami, Nasser Samadi   +7 more
doaj   +1 more source

Hepatic peroxisome proliferator-activated receptor γ and α-mRNA expression in HCV-infected adults is decreased by HIV co-infection and is also affected by ethnicity

Clinics, 2015
OBJECTIVE: To determine peroxisome proliferator activated receptor α and γ mRNA expression in liver tissue of hepatitis C virus-infected patients with and without human immunodeficiency virus and its possible contribution to an acceleration of liver ...
Nathan J. Shores, Maria Cássia Mendes-Corrêa, Ivana Maida, JoLyn Turner, Kevin P. High, Sergio Babudieri, Marina Núãez   +6 more
doaj   +1 more source

A role for peroxisome proliferator-activated receptors in the immunopathology of schistosomiasis? [PDF]

, 2012
Peroxisome proliferator-activated receptors (PPARs) have been demonstrated to have a role in immune regulation. In general, they are anti-inflammatory and promote Th2 type responses, and they are associated with the alternative activation of macrophages.
Allen, JT, Anthony, BJ, Li, Y, McManus, D   +3 more
core   +4 more sources